Infimab (infliximab biosimilar) - Sun Pharma, Reliance Life Sciences
Epirus: Corporate Overview (Epirus Biopharmaceuticals) - Feb 7, 2016 - Anticipated initiation of P3 global registration program by H2 2016; Anticipated global market filings in 2017 
Anticipated new P3 trial • Anticipated regulatory Biosimilar
http://files.shareholder.com/downloads/AMDA-30YNO0/1471780370x0x872165/D50CA62A-2940-4B94-A5BF-06ECC0C3C773/Corp_Slide_deck.pdf
 
Feb 7, 2016
 
.
 
493e55ff-02f0-4ab1-81e1-0340f433e6f7.jpg

cce8ec21-7df2-4ccb-bf27-558be6277611.jpg